Akari Therapeutics Plc

For the period ended Mar 31, 2026. Filed May 19, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 19, 2026

AKTX$7.37-4.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Shareholders’ Equity

(amounts in thousands, except share data)

	Accumulated
Additional · Capital · Other · Total
Share Capital · Paid-in- · Redemption · Comprehensive · Accumulated · Shareholders’
	Shares	Amount	Capital	Reserve	Loss	Deficit	Equity
Balance, December 31, 2025	90,536,879,533	$—	$234,318	$59,342	$(782)	$(264,550)	$28,328
Issuance of share capital related to financing, net of issuance costs	1,030,130,000	—	188	—	—	—	188
Stock-based compensation	—	—	305	—	—	—	305
Foreign currency translation	—	—	—	—	14	—	14
Net loss	—	—	—	—	—	(14,455)	(14,455)
Balance, March 31, 2026	91,567,009,533	$—	$234,811	$59,342	$(768)	$(279,005)	$14,380

	Accumulated
Additional · Capital · Other · Total
Share Capital · Paid-in- · Redemption · Comprehensive · Accumulated · Shareholders’
	Shares	Amount	Capital	Reserve	Loss	Deficit	Equity
Balance, December 31, 2024	53,186,919,523	$5,319	$212,706	$52,194	$(738)	$(247,252)	$22,229
Issuance of share capital related to financing, net of issuance costs	4,566,062,000	457	1,785	—	—	—	2,242
Stock-based compensation	—	—	1,015	—	—	—	1,015
Foreign currency translation	—	—	—	—	(35)	—	(35)
Net loss	—	—	—	—	—	(3,705)	(3,705)
Balance, March 31, 2025	57,752,981,523	$5,776	$215,506	$52,194	$(773)	$(250,957)	$21,746

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.